Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor

NCT04465643 is registered in ClinicalTrials.gov with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as lead sponsor.

NCT NCT04465643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04465643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase
Phase 1
Overall status
Completed
Start date
June 8, 2021
Completion date
July 30, 2025
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nerve sheath tumors